Daily Medication Pearl: Advair Diskus (Fluticasone and Salmeterol)
Advair Diskus is indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease.
Medication Pearl of the Day: Advair Diskus (Fluticasone and Salmeterol)
Indication: Advair Diskus is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist indicated for maintenance treatment of asthma in patients 4 years of age and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Insight:
- Dosing: Maintenance treatment of asthma in patients ≥12 years: 1 inhalation of Advair Diskus 100/50, 250/50, or 500/50 twice daily. Maintenance treatment of asthma in patients 4 to 11 years: 1 inhalation of Advair Diskus 100/50 twice daily. Maintenance treatment of COPD: 1 inhalation of Advair Diskus 250/50 twice daily
- Dosage forms: Diskus device containing a combination of fluticasone propionate (100, 250, or 500 mcg) and salmeterol (50 mcg) as an oral inhalation powder.
- Adverse events: Most common adverse reactions (incidence ≥3%) are upper respiratory tract infection or inflammation, pharyngitis, dysphonia, oral candidiasis, bronchitis, cough, headaches, nausea and vomiting.
- Mechanism of action: Fluticasone propionate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. Salmeterol is a selective, long-acting beta2-adrenergic agonist.
- Manufacturer: GSK
Reference:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025